Literature DB >> 15967088

Treatment of Convulsive and Nonconvulsive Status Epilepticus.

Trudy Pang1, Lawrence J Hirsch.   

Abstract

Status epilepticus (SE) should be treated as quickly as possible with full doses of medications as detailed in a written hospital protocol. Lorazepam is the drug of choice for initial treatment. If intravenous access is not immediately available, then rectal diazepam or nasal or buccal midazolam should be given. Prehospital treatment of seizures by emergency personnel is effective and safe, and may prevent cases of refractory SE. Home treatment of prolonged seizures or clusters with buccal, nasal, or rectal benzodiazepines should be considered for all at-risk patients. Nonconvulsive SE is underdiagnosed. An electroencephalogram should be obtained immediately in anyone with unexplained alteration of behavior or mental status and after convulsive SE if the patient does not rapidly awaken. Delay in diagnosis of SE is associated with a worse outcome and a higher likelihood of poor response to treatment. For refractory SE, continuous intravenous midazolam and propofol (alone or in combination) are rapidly effective. Randomized trials are needed to determine the best treatment for SE after lorazepam.

Entities:  

Year:  2005        PMID: 15967088     DOI: 10.1007/s11940-005-0035-x

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.972


  55 in total

1.  Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial.

Authors:  R C Scott; F M Besag; B G Neville
Journal:  Lancet       Date:  1999-02-20       Impact factor: 79.321

2.  Home and hospital treatment of acute seizures in children with nasal midazolam.

Authors:  P Y Jeannet; E Roulet; M Maeder-Ingvar; M Gehri; A Jutzi; T Deonna
Journal:  Eur J Paediatr Neurol       Date:  1999       Impact factor: 3.140

3.  It's time to revise the definition of status epilepticus.

Authors:  D H Lowenstein; T Bleck; R L Macdonald
Journal:  Epilepsia       Date:  1999-01       Impact factor: 5.864

4.  Continuous EEG monitoring and midazolam infusion for refractory nonconvulsive status epilepticus.

Authors:  J Claassen; L J Hirsch; R G Emerson; J E Bates; T B Thompson; S A Mayer
Journal:  Neurology       Date:  2001-09-25       Impact factor: 9.910

5.  Prevalence of nonconvulsive status epilepticus in comatose patients.

Authors:  A R Towne; E J Waterhouse; J G Boggs; L K Garnett; A J Brown; J R Smith; R J DeLorenzo
Journal:  Neurology       Date:  2000-01-25       Impact factor: 9.910

6.  A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus.

Authors:  B K Alldredge; A M Gelb; S M Isaacs; M D Corry; F Allen; S Ulrich; M D Gottwald; N O'Neil; J M Neuhaus; M R Segal; D H Lowenstein
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

7.  N-methyl-D-asparate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat.

Authors:  A M Mazarati; C G Wasterlain
Journal:  Neurosci Lett       Date:  1999-04-23       Impact factor: 3.046

8.  Ketamine controls prolonged status epilepticus.

Authors:  D J Borris; E H Bertram; J Kapur
Journal:  Epilepsy Res       Date:  2000-12       Impact factor: 3.045

9.  Treating repetitive seizures with a rectal diazepam formulation: a randomized study. The North American Diastat Study Group.

Authors:  J J Cereghino; W G Mitchell; J Murphy; R L Kriel; W E Rosenfeld; E Trevathan
Journal:  Neurology       Date:  1998-11       Impact factor: 9.910

10.  Determinants of mortality in status epilepticus.

Authors:  A R Towne; J M Pellock; D Ko; R J DeLorenzo
Journal:  Epilepsia       Date:  1994 Jan-Feb       Impact factor: 5.864

View more
  10 in total

1.  Robust control of burst suppression for medical coma.

Authors:  M Brandon Westover; Seong-Eun Kim; ShiNung Ching; Patrick L Purdon; Emery N Brown
Journal:  J Neural Eng       Date:  2015-05-28       Impact factor: 5.379

2.  Treatment of nonconvulsive status epilepticus.

Authors:  Trudy Pang; Frank W Drislane
Journal:  Curr Treat Options Neurol       Date:  2012-08       Impact factor: 3.598

Review 3.  Generalised convulsive status epilepticus: an overview.

Authors:  R Nandhagopal
Journal:  Postgrad Med J       Date:  2006-11       Impact factor: 2.401

4.  Factors related to delays in pre-hospital management of status epilepticus.

Authors:  Leena Kämppi; Harri Mustonen; Seppo Soinila
Journal:  Neurocrit Care       Date:  2015-02       Impact factor: 3.210

Review 5.  Intranasal delivery of antiepileptic medications for treatment of seizures.

Authors:  Daniel P Wermeling
Journal:  Neurotherapeutics       Date:  2009-04       Impact factor: 7.620

6.  Rapid delivery of diazepam from supersaturated solutions prepared using prodrug/enzyme mixtures: toward intranasal treatment of seizure emergencies.

Authors:  Mamta Kapoor; Tate Winter; Lev Lis; Gunda I Georg; Ronald A Siegel
Journal:  AAPS J       Date:  2014-04-04       Impact factor: 4.009

7.  Can endotracheal intubation be the first step in management of nonconvulsive status epilepticus?: A case report.

Authors:  Saad Warraich; Abbas Ali; Atif Nizami; Moiz Bakhiet
Journal:  Medicine (Baltimore)       Date:  2018-02       Impact factor: 1.817

Review 8.  First-line management of canine status epilepticus at home and in hospital-opportunities and limitations of the various administration routes of benzodiazepines.

Authors:  Marios Charalambous; Holger A Volk; Luc Van Ham; Sofie F M Bhatti
Journal:  BMC Vet Res       Date:  2021-03-04       Impact factor: 2.741

Review 9.  Intranasal treatment of central nervous system dysfunction in humans.

Authors:  Colin D Chapman; William H Frey; Suzanne Craft; Lusine Danielyan; Manfred Hallschmid; Helgi B Schiöth; Christian Benedict
Journal:  Pharm Res       Date:  2012-11-08       Impact factor: 4.200

Review 10.  Dysregulation of GABAergic Signaling in Neurodevelomental Disorders: Targeting Cation-Chloride Co-transporters to Re-establish a Proper E/I Balance.

Authors:  Enrico Cherubini; Graziella Di Cristo; Massimo Avoli
Journal:  Front Cell Neurosci       Date:  2022-01-05       Impact factor: 5.505

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.